AbbVie ABBV Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's additional paid-in capital?
- AbbVie (ABBV) reported additional paid-in capital of $22.96B in Q1 2026.
- How has AbbVie's additional paid-in capital changed year-over-year?
- AbbVie's additional paid-in capital increased by 5.3% year-over-year, from $21.81B to $22.96B.
- What is the long-term trend for AbbVie's additional paid-in capital?
- Over 5 years (2020 to 2025), AbbVie's additional paid-in capital has grown at a 5.3% compound annual growth rate (CAGR), from $17.38B to $22.5B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.